

September 29, 2006

FILE GOPY

Leslie Sands Lupin Pharmaceuticals, Inc. Harborplace Towers 111 South Calvert Street, 21st Floor Baltimore, Maryland 21209

Dear Ms. Sands:

Your petition requesting the Food and Drug Administration to permit an ANDA Suitability for Fexofenadine Hydrochloride for Oral Suspension, was received by this office on 09/29/2006. It was assigned docket number 2006P-0397/CP1 and it was filed on 09/29/2006. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Gennie C. Butler, Director

Division of Dockets Management

Office of Management Programs

Office of Management

2006P-0397

ACK